Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H7F5O4 |
| Molecular Weight | 286.1522 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=C(OCC(F)(F)C(F)(F)F)C=C1O
InChI
InChIKey=BLEWPNAUDGZWPU-UHFFFAOYSA-N
InChI=1S/C10H7F5O4/c11-9(12,10(13,14)15)4-19-5-1-2-6(8(17)18)7(16)3-5/h1-3,16H,4H2,(H,17,18)
| Molecular Formula | C10H7F5O4 |
| Molecular Weight | 286.1522 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:50 GMT 2023
by
admin
on
Sat Dec 16 11:32:50 GMT 2023
|
| Record UNII |
NM6AF3AW9M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
651331-92-9
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY | |||
|
DTXSID00430848
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY | |||
|
NM6AF3AW9M
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY | |||
|
9795862
Created by
admin on Sat Dec 16 11:32:50 GMT 2023 , Edited by admin on Sat Dec 16 11:32:50 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
No serious nor causal adverse reactions were reported in this study, but patients reported numerous local symptoms after product applications, especially itching, tingling, tightness, and heat/burning sensations at frequencies that were similar for vehicle, 1% UR-1505, and 2% UR-1505
more frequent with 0.5% UR-1505 and lowest for tacrolimus. This study found that UR-1505 may not be a suitable option for the treatment of atopic dermatitis due to its lack of clinically relevant effect compared with its vehicle and 0.1% tacrolimus ointment.
|
||
|
ACTIVE MOIETY |
UR-1505 is a novel salicylate derivative compound that has been demonstrated to selectively down-regulate T-cell activation. The aim of the present study was to elucidate the mechanisms involved in the intestinal anti-inflammatory effects of UR-1505 in 2 protocols of a dextran sodium sulfate (DSS) model of rat colitis: acute and established colitis. These results suggest that this compound is a good candidate for inducing remission or maintaining therapies in human inflammatory bowel disease (IBD). Moreover, the different results obtained by UR-1505 in these 2 protocols of colitis induction (acute initial colitis versus established colitis) confirm the importance of selection and optimization of the experimental model to evaluate the drugs to be used in IBD therapy.
|
||
|
ACTIVE MOIETY |
Class: Antipsoriatic, Salicylate: Mechanism of Action: Lymphocyte inhibitor, Tumour necrosis factor alpha inhibitor; Highest Development Phase: Phase II Atopic dermatitis, Discontinued for Inflammatory bowel disease, Psoriasis, Rheumatoid arthritis and Transplant rejection; Most Recent Events: 01 Jul 2015 Palau Pharma completes a phase II trial in Atopic dermatitis in France (EudraCT2007-002550-27), 24 Jul 2007 Discontinued - Preclinical for Transplant rejection in Spain (unspecified route), 24 Jul 2007 Discontinued - Preclinical for Rheumatoid arthritis in Spain (PO)
|
